Newbury Pharmaceuticals Signed Iraq Supply Agreement
The firm secured a ten-year exclusivity deal to distribute 40 injectable medicines in the Iraqi market.
Updated on Sept. 30, 2026 in Healthcare
Live Poll
Do you believe partnerships with foreign pharmaceutical firms improve medicine access in your area?
Newbury Pharmaceuticals AB has finalized a ten-year exclusivity agreement with a Chinese manufacturer to supply 40 pharmaceutical products. These injectable medicines are intended for hospital and acute care settings, with sales conducted under the company's own brand names.
Why it matters
The deal significantly expands the company's international footprint into the Iraqi healthcare market. By pursuing an import licence, the firm aims to establish a supply chain for essential acute care treatments prior to receiving full marketing authorization.
The agreement covers a portfolio of 40 individual pharmaceutical products produced under a 10-year exclusivity window. Newbury Pharmaceuticals AB has already submitted applications for an import licence to facilitate early supply.
The players
Newbury Pharmaceuticals AB
This Swedish-based pharmaceutical firm specializes in developing and distributing medical products for global markets.
Newbury Pharmaceuticals S.A.
This is a subsidiary entity of Newbury Pharmaceuticals AB that acts as the primary vehicle for this international manufacturing deal.
The details
The arrangement was finalized through the subsidiary Newbury Pharmaceuticals S.A. to secure a pipeline of hospital-grade injectable treatments for distribution in Iraq.
Timeline
The exclusivity agreement was signed on September 30, 2026.
The contract terms span a duration of 10 years.
Market Landscape
This move reflects a broader industry push to secure stable supply chains for critical hospital medicines through long-term partnerships with specialized manufacturers. The strategy positions the firm to capture emerging market share by diversifying its product portfolio ahead of competitors.
Healthcare providers in the region may see an increase in the availability of specialized injectable medicines once the import licence is granted. Patients in hospital and acute care settings will likely have access to a broader range of branded treatments as the company integrates these 40 new products into its network.
The takeaway
Securing long-term manufacturing rights allows pharmaceutical companies to stabilize product delivery in high-demand markets. Strategic partnerships like this one illustrate how firms mitigate supply risks to ensure essential medicines remain accessible to hospital patients.
Further reading
For broader trends in medical supply distribution, explore the latest updates in Healthcare.
Source note: This article includes information reported by Iraq Business News | All the latest business news from Iraq.
Live Poll
Do you believe partnerships with foreign pharmaceutical firms improve medicine access in your area?
